Introduction: Urinary tract infections (UTI) are among the most common complications in persons with neurogenic lower urinary tract dysfunction (NLUTD) due to spinal cord injury (SCI). As both asymptomatic bacteriuria and UTI are frequently treated with antibiotics, concerns about multidrug resistance arise. Therefore, we analyzed the bacterial spectrum in the urine and the resistance patterns of the strains over time in patients with NLUTD due to SCI. Methods: In a systematic chart review, we identified all microbiologic urine test results including resistance patterns of persons with SCI in a tertiary referral hospital at 2 time periods (2010–2011 and 2017–2018). We assessed the frequency of the bacterial strains, the resistance patterns of the 5 most frequent bacteria, and the use of antibiotics for in- as well as for outpatients. Results: From 2010 to 2011, 1,308 (outpatients) and 2,479 (inpatients) bacterial strains were detected in the urinalyses performed; these numbers rose to 3,162 and 6,112 during 2017–2018, respectively. The most frequently detected bacteria during both time periods were Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae/variicola, Streptococcus viridans, Pseudomonas aeruginosa, and coagulase negative Staphylococci. Fluoroquinolones were the most frequently used antibiotics during both time periods. Despite its frequent use, no relevant increase in resistance against fluoroquinolones was detected. The most prominent increase in resistance appeared in E. coli against amocixillin/clavulanic acid in inpatients (from 26.0 to 38.5%). Discussion and Conclusions: Although fluoroquinolones were used frequently, we did not observe an increased resistance against these antibiotics over time in the urine of patients with SCI.

1.
Gamé
X
,
Castel-Lacanal
E
,
Bentaleb
Y
,
Thiry-Escudié
I
,
De Boissezon
X
,
Malavaud
B
, et al.
Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections
.
Eur Urol
.
2008
;
53
(
3
):
613
8
. .
2.
Vigil
HR
,
Hickling
DR
.
Urinary tract infection in the neurogenic bladder
.
Transl Androl Urol
.
2016
;
5
(
1
):
72
87
. .
3.
Krebs
J
,
Wöllner
J
,
Pannek
J
.
Risk factors for symptomatic urinary tract infections in individuals with chronic neurogenic lower urinary tract dysfunction
.
Spinal Cord
.
2016
;
54
(
9
):
682
6
. .
4.
Anderson
CE
,
Chamberlain
JD
,
Jordan
X
,
Kessler
TM
,
Luca
E
,
Möhr
S
, et al.
Bladder emptying method is the primary determinant of urinary tract infections in patients with spinal cord injury: results from a prospective rehabilitation cohort study
.
BJU Int
.
2019
;
123
(
2
):
342
52
. .
5.
Esclarin De Ruz
A
,
Garcia Leoni
E
,
Herruzo Cabrera
R
.
Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury
.
J Urol
.
2000
;
164
(
4
):
1285
9
.
6.
Biering-Sorensen
F
,
Nielans
HM
,
Dørflinger
T
,
Sørensen
B
.
Urological situation five years after spinal cord injury
.
Scand J Urol Nephrol
.
1999
;
33
(
3
):
157
61
.
7.
Groen
J
,
Pannek
J
,
Castro Diaz
D
,
Del Popolo
G
,
Gross
T
,
Hamid
R
, et al.
Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology
.
Eur Urol
.
2016
;
69
(
2
):
324
33
. .
8.
Pannek
J
.
Treatment of urinary tract infection in persons with spinal cord injury: guidelines, evidence, and clinical practice. A questionnaire-based survey and review of the literature
.
J Spinal Cord Med
.
2011
;
34
(
1
):
11
5
. .
9.
Hinkel
A
,
Finke
W
,
Bötel
U
,
Gatermann
SG
,
Pannek
J
.
Increasing resistance against antibiotics in bacteria isolated from the lower urinary tract of an outpatient population of spinal cord injury patients
.
Urol Int
.
2004
;
73
(
2
):
143
8
. .
10.
Bauer
AW
,
Kirby
WM
,
Sherris
JC
,
Turck
M
.
Antibiotic susceptibility testing by a standardized single disk method
.
Am J Clin Pathol
.
1966
;
45
(
4
):
493
6
. .
11.
Krebs
J
,
Wöllner
J
,
Pannek
J
.
Bladder management in individuals with chronic neurogenic lower urinary tract dysfunction
.
Spinal Cord
.
2016
;
54
(
8
):
609
13
. .
12.
Zhu
DM
,
Li
QH
,
Shen
Y
,
Zhang
Q
.
Risk factors for quinolone-resistant Escherichia coli infection: a systematic review and meta-analysis
.
Antimicrob Resist Infect Control
.
2020 Jan 9
;
9
(
1
):
11
..
13.
Yoon
SB
,
Lee
BS
,
Lee
KD
,
Hwang
SI
,
Lee
HJ
,
Han
ZA
.
Comparison of bacterial strains and antibiotic susceptibilities in urinary isolates of spinal cord injury patients from the community and hospital
.
Spinal Cord
.
2014
;
52
(
4
):
298
301
. .
14.
Kang
MS
,
Lee
BS
,
Lee
HJ
,
Hwang
SW
,
Han
ZA
.
Prevalence of and risk factors for multidrug-resistant bacteria in urine cultures of spinal cord injury patients
.
Ann Rehabil Med
.
2015
;
39
(
5
):
686
95
. .
15.
Wolfensberger
A
,
Sax
H
,
Weber
R
,
Zbinden
R
,
Kuster
SP
,
Hombach
M
.
Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: influence on cumulative hospital antibiograms
.
PLoS One
.
2013
;
8
(
11
):
e79130
. .
16.
Karam
MRA
,
Habibi
M
,
Bouzari
S
.
Relationships between virulence factors and antimicrobial resistance among Escherichia coli isolated from urinary tract infections and commensal isolates in Tehran, Iran
.
Osong Public Health Res Perspect
.
2018
;
9
(
5
):
217
24
. .
17.
Laxminarayan
R
,
Duse
A
,
Wattal
C
,
Zaidi
AK
,
Wertheim
HF
,
Sumpradit
N
, et al.
Antibiotic resistance-the need for global solutions
.
Lancet Infect Dis
.
2013
;
13
(
12
):
1057
98
. .
18.
Guillemot
D
.
Antibiotic use in humans and bacterial resistance
.
Curr Opin Microbiol
.
1999
;
2
(
5
):
494
8
. .
19.
Goetz
LL
,
Cardenas
DD
,
Kennelly
M
,
Bonne Lee
BS
,
Linsenmeyer
T
,
Moser
C
, et al.
International spinal cord injury urinary tract infection basic data set
.
Spinal Cord
.
2013
;
51
(
9
):
700
4
. .
20.
Böthig
R
,
Domurath
B
,
Kaufmann
A
,
Bremer
J
,
Vance
W
,
Kurze
I
.
Neuro-urologische Diagnostik und Therapie bei Funktionsstörungen des unteren Harntrakts nach einer Rückenmarkschädigung. S2k-Leitlinie der Deutschsprachigen Medizinischen Gesellschaft für Paraplegie (DMGP), AWMF-Register Nr: 179/001 [Neuro-urological diagnosis and therapy of lower urinary tract dysfunction in patients with spinal cord injury: S2k Guideline of the German-Speaking Medical Society of Paraplegia (DMGP), AWMF register no. 179/001] (German)
.
Urologe A
.
2017
;
56
(
6
):
785
92
.
21.
Pannek
J
,
Wöllner
J
.
Management of urinary tract infections in patients with neurogenic bladder: challenges and solutions
.
Res Rep Urol
.
2017
;
9
:
121
7
. .
22.
Ibrahim
NH
,
Maruan
K
,
Mohd Khairy
HA
,
Hong
YH
,
Dali
AF
,
Neoh
CF
.
Economic evaluations on antimicrobial stewardship programme: a systematic review
.
J Pharm Pharm Sci
.
2017
;
20
(
1
):
397
406
. .
23.
Kitagawa
K
,
Shigemura
K
,
Nomi
M
,
Takami
N
,
Yamada
N
,
Fujisawa
M
.
Use of oral third generation cephalosporins and quinolones and occurrence of antibiotic-resistant strains in the neurogenic bladder (NB) outpatient setting: a retrospective chart audit
.
Spinal Cord
.
2020
;
58
(
6
):
705
10
. .
24.
Lebentrau
S
,
Gilfrich
C
,
Vetterlein
MW
,
Schumacher
H
,
Spachmann
PJ
,
Brookman-May
SD
, et al.
Impact of the medical specialty on knowledge regarding multidrug-resistant organisms and strategies toward antimicrobial stewardship
.
Int Urol Nephrol
.
2017
;
49
(
8
):
1311
8
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.